The NANOBICAR Consortium successfully gathered in the vibrant city of Valencia on February 16th and 17th, 2026, for its highly anticipated Annual Meeting. This milestone event brought together experts from 12 partner organizations across 5 countries, all united by a singular mission: revolutionizing the fight against bacterial infections. By developing a cutting-edge immunotherapeutic approach using mRNA-loaded lipid nanoparticles, the project aims to eliminate both intra- and extracellular bacteria. With tuberculosis serving as the primary proof of concept, NANOBICAR is paving the way for a safe, cost-effective, and resistance-free treatment alternative specifically designed to thrive in high-burden and low-resource settings.
The two-day summit provided a critical platform to review the impressive results achieved during the project’s inaugural year, which kicked off in February 2025. Partners engaged in a series of insightful, high-energy discussions to analyze early data and refine the technical roadmap for the coming year. These collaborative sessions were instrumental in planning the next phase of experiments and aligning the project’s strategic direction for 2026. As the consortium moves forward, the synergy displayed in Valencia reinforces our commitment to delivering a transformative solution for global public health challenges.